Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Historic Output Of Disease-Specific Guidances Is Among Gottlieb's Legacies At US FDA

Mar 07 2019

• By Michael Cipriano

Related Content

Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA

May 12 2018

Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?

Apr 24 2018

Hemophilia Gene Therapy Studies Could Use Non-Inferiority Design, US FDA Suggests

Jul 16 2018

The Luxturna Model: Spark’s Approach To Retinal Disease Endpoint Embraced In Gene Therapy Guidance

Jul 12 2018

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Sep 12 2017

Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform

Sep 14 2017

Peter Stein Takes Short Path To Director Of US FDA Drug Office

Dec 10 2018

Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update

Dec 20 2018

Related Companies

GSK plc

Additional Topics

United States Research & Development Drug Approval Standards Regulation BioPharmaceutical

More from R&D

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window